Can you take Gamifant with Streptococcus salivarius?
1 drug interaction and 4 additional warnings found for the following 2 drugs:
- Gamifant (emapalumab)
- streptococcus salivarius
Drug interactions
Moderate drug interactions
Moderate:
emapalumab streptococcus salivarius
Applies to: Gamifant (emapalumab) and streptococcus salivarius
If you are currently being treated or have recently been treated with emapalumab, you should let your doctor know before using streptococcus salivarius.
Depending on the dose and length of time you have been on emapalumab, you may be at risk for developing rare infections from exposure to products containing live bacteria or yeast.
Depending on your overall health and medical condition, it may be advisable to avoid using streptococcus salivarius until your immune system has recovered from the effects of emapalumab.
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
4 potential interactions Applies to: 4 conditions, including Infection, Tuberculosis, Latent, History, Tuberculosis, and Vaccination.
History, Tuberculosis
Moderate:
Gamifant
The emapalumab in Gamifant has a moderate potential interaction with History, Tuberculosis.
Due to the increased risk of infection with emapalumab, patients at risk for tuberculosis (TB) or with a known positive TB screening test result should be given TB prophylaxis during therapy. All patients should be assessed for TB risk factors and tested for latent infection prior to treatment.
Infection
Major:
Gamifant
The emapalumab in Gamifant has a major potential interaction with Infection.
Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.
Tuberculosis, Latent
Moderate:
Gamifant
The emapalumab in Gamifant has a moderate potential interaction with Tuberculosis, Latent.
Due to the increased risk of infection with emapalumab, patients at risk for tuberculosis (TB) or with a known positive TB screening test result should be given TB prophylaxis during therapy. All patients should be assessed for TB risk factors and tested for latent infection prior to treatment.
Vaccination
Moderate:
Gamifant
The emapalumab in Gamifant has a moderate potential interaction with Vaccination.
Do not administer live or live attenuated vaccines to patients receiving emapalumab and for at least 4 weeks after the last dose of emapalumab. The safety of immunization with live vaccines during or following therapy has not been studied.
Report options
More resources
Gamifant
A total of 201 drugs are known to interact with Gamifant.
- Gamifant is in the drug class selective immunosuppressants.
- Gamifant is used to treat the following conditions:
streptococcus salivarius
A total of 286 drugs are known to interact with streptococcus salivarius.
- Streptococcus salivarius is in the drug class probiotics.
- Streptococcus salivarius is used to treat Oral and Dental Conditions.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.